There Is No Interaction Between BMI and SGLT2 Inhibitor Efficacy in HF, Review Finds

Among patients with heart failure (HF), those taking dapaglifozin or empaglifozin had a 30% odds reduction in HF hospitalization, 14% odds reduction in cardiovascular mortality, and a 10% odds reduction in all-cause mortality compared with patients taking placebo.

Related Keywords

United States ,American ,Wolfram Doehner , ,Olivier Le Moal ,American Journal ,Managed Care ,Intern Emerg ,Eurj Heart ,Heart Fail ,Heart Failure ,Cardiovascular ,Sglt2 Inhibitor ,Dapaglifozin ,Empaglifozin ,Hf ,Internal And Emergency Medicine ,Hfref ,Hfpef ,